EUVIMEDEUVIMED entdecken
Crossref

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

Emi Tanaka, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa und 47 weitere

Oncology · 03.08.2026 · 1-26

DOI: 10.1159/000553349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 03.08.2026. Verfasst von Emi Tanaka und 58 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The lymphocyte-to-monocyte ratio (LMR) has emerged as a potential immune-related biomarker; however, its prognostic significance in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev) remains unclear. To investigate the prognostic significance of the LMR in patients with unresectable HCC treated with Atezo/Bev.

Methods

This multicentre study included 941 patients with unresectable HCC treated with Atezo/Bev therapy at 30 institutions in Japan. The optimal LMR cutoff value was determined using time-dependent receiver operating characteristic (ROC) analysis. Multivariate survival analyses were performed for progression-free survival (PFS) and overall survival (OS). The prognostic utility of the LMR was compared with that of the neutrophil-to-lymphocyte ratio (NLR) using integrated discrimination improvement and net reclassification improvement.

Results

Time-dependent ROC analysis identified an optimal LMR cutoff value of 3.6 based on median OS. The median PFS was 5.6 months in patients with an LMR < 3.6 and 8.9 months in those with an LMR ≥ 3.6 (P

Schlagwörter

Stichwörter der Autor:innen

AtezolizumabBevacizumabHepatocellular carcinomaLymphocyte-to-monocyte ratioSurvival

Autor:innen und Institutionen

  • Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
  • Department of Gastroenterology and Neurology, Kagawa University, Takamatsu, Japan.

Zitieren

APA

Tanaka, E., Tada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Tsuji, K., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., Kawata, K., …, & RELPEC Group (2026). Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Oncology, 1-26. https://doi.org/10.1159/000553349

Vancouver

Tanaka E, Tada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, et al. Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Oncology. 2026:1-26. doi:10.1159/000553349

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Emi and Tada, Toshifumi and Hiraoka, Atsushi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Nishimura, Takashi and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Tanaka, Hironori and Toyoda, Hidenori and Ogawa, Chikara and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Tamai, Hideyuki and Komatsu, Shohei and Matsuura, Takanori and Ueda, Yoshihide and Matono, Tomomitsu and Kim, Soo Ki and Ohama, Hideko and Tada, Fujimasa and Nakamura, Shinichiro and Nakamura, Yoshiko and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Nagano, Takuya and Tanaka, Kazunari and Koshiyama, Yuichi and Kanayama, Yuki and Noritake, Hidenao and Enomoto, Hirayuki and Matsui, Kosuke and Kaibori, Masaki and Okamura, Jumpei and Fukumoto, Takumi and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and HCC 48 Group, HCC 48 Group and RELPEC Group, RELPEC Group},
  title = {Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab},
  journal = {Oncology},
  year = {2026},
  pages = {1--26},
  doi = {10.1159/000553349}
}
Kostenlos starten →